Detailed price information for Lantheus Holdings (LNTH-Q) from The Globe and Mail including charting and trades.

The CAPTAIN trial shows faster recovery, fewer complications, and better early function with the minimally invasive therapy ...

ORNL is a leader both in developing advanced radiotherapies and in providing the radioisotopes needed for those therapies.

Tagawa, MD, identified 3 primary clinical scenarios where PSMA PET scans have become the established standard for prostate ...

Prostate-specific membrane androgen PET/CT can help clinicians intensify or de-escalate care for men with prostate cancer who ...

As a result, researchers have explored less invasive options that aim to treat the cancer while preserving quality of life. One such approach is TULSA, which uses real-time MRI guidance to deliver ...

Scans that make prostate cancer cells glow can eliminate the need for invasive biopsies and cut false positive—and they're ...

Discusses First Clinical Outcomes and Precision of TULSA from the CAPTAIN Trial in Prostate Cancer March 13, 2026 11:30 ...

First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to ...

Prostate cancer is one of the most common cancers affecting men around the world. It develops in the prostate, a small gland ...

Koelis, SAS ("Koelis" or the "Company", a leader and innovator in MRI-ultrasound fusion guidance for prostate cancer ...

Profound Medical Corp. (NASDAQ:PROF) Q4 2025 Earnings Call Transcript March 6, 2026 Operator: Good day, and thank you for ...